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INTRODUCTION
Severe persistent thrombocytopenia after myeloablative
conditioning regimens and hematopoietic stem cell trans-
plantation (HSCT) increases the risk of life-threatening
hemorrhage and requires close monitoring and support with
blood products [1-6]. Continuous support with platelet
transfusions is associated with morbidity related to transfu-
sion reactions, platelet allo-immunization, and transfusion-
related viral infections. There is also a signiﬁcant ﬁnancial
burden associated with platelet transfusion support [2]. New
treatments that could decrease the period of thrombocy-
topenia could have signiﬁcant clinical beneﬁts [7-10].
The ligand for c-mpl is a critical cytokine that regulates
platelet numbers in the peripheral circulation [11]. In c-mpl
ligand and c-mpl knock-out mice, there is a marked reduction
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ABSTRACT
This study investigates the potential role of the recombinant c-mpl ligands (recombinant human thrombopoietin
[rhTPO] and pegylated recombinant human megakaryocyte growth and development factor [PEG-rhMGDF]) on
the recovery of platelet counts after TBI with and without allogeneic hematopoietic stem cell transplantation
(HSCT) in an established canine model. Initially, 3 cohorts, each with 2 nonirradiated dogs, received increasing
doses of rhTPO (5 µg/kg per day; 10 µg/kg per day; 20 µg/kg per day) for 7 days to determine the optimal dose. The
dose of 10 µg/kg per day of rhTPO was selected for subsequent studies. Ten dogs then received either rhTPO or
placebo for 28 days after 200 cGy TBI without HSCT. The rhTPO group had fewer days with platelet counts
<20,000/µL (9.8 days versus 17.8 days, P < .05) and significantly increased granulocyte counts (n = 5) compared to
the controls (n = 5). RhTPO-specific antibodies developed in 2 dogs, which caused a significant but transient
decrease of the platelet counts. Retreatment of these sensitized dogs with rhTPO resulted in profound transient
decreases in platelet counts. In the next study, 20 dogs received either PEG-rhMGDF or placebo for 21 days after
920 cGy TBI and allogeneic HSCT. The median time to platelet recovery (>20,000/µL) for the PEG-rhMGDF
group (n = 10) was 14.0 days compared to 15.5 days for the control group (n = 10; log rank, P = .35). There were no
significant differences in the total time to platelet counts <20,000/µL or in the time to recover neutrophil counts
>500/µL. The effects of rhTPO on recovery of platelet and granulocyte counts after sublethal TBI were modest,
and no effects of PEG-rhMGDF were observed on hematopoietic recovery after high-dose TBI and allogeneic
HSCT. The significant effect that rhTPO-specific antibodies had on the platelet counts may limit the clinical role of
recombinant c-mpl ligands unless sensitization can be prevented.
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but not an absence of marrow megakaryocytes and platelets
[12]. In humans, mutations of c-mpl associated with a loss of
function cause congenital amegakaryocytic thrombocytope-
nia [13]. The ligand for c-mpl is relatively lineage speciﬁc,
works both alone and synergistically with other cytokines to
support early hematopoietic progenitor production and
megakaryocyte colony formation, and acts at a late stage of
development to increase megakaryocyte size, polyploidiza-
tion, and expression of differentiation markers [14-18]. Two
forms of recombinant human c-mpl ligand were developed
for clinical evaluation: the full-length molecule known as
recombinant human thrombopoietin (rhTPO), and a trun-
cated version, bound to polyethylene glycol and known as
pegylated recombinant human megakaryocyte growth and
development factor (PEG-rhMGDF). Both recombinant
forms have shown potent platelet stimulatory activity and
excellent clinical tolerance in different species [7,8,10,19-21].
In vivo, treatment with c-mpl ligands (rhTPO and PEG-
rhMGDF) has increased platelet counts and expanded the
numbers of megakaryocytes and their progenitors in the
marrow and spleen [14].
In this study, the effect of recombinant forms of c-mpl
ligand on recovery of platelet counts after a sublethal dose
of a cytotoxic agent (total body irradiation [TBI] 200 cGy)
without HSCT and after a high-dose conditioning regimen
(TBI 920 cGy) with HSCT was investigated in an estab-
lished canine transplantation model [22]. RhTPO-specific
antibodies developed in some dogs, which caused a signiﬁ-
cant decrease of platelet counts.
MATERIALS AND METHODS
Experimental Animals
Forty-one random-bred dogs, 6 to 18 months of age and
weighing 6 to 15 kg, were entered into the study. The dogs
were either raised at the Fred Hutchinson Cancer Research
Center (FHCRC) or obtained from breeders licensed by the
U.S. Department of Agriculture. Dogs were quarantined on
arrival, screened for evidence of disease, and observed for a
minimum of 2 months prior to entering into protocol. They
were dewormed and vaccinated for rabies, distemper, lepto-
spirosis, papillomavirus, hepatitis, and parvovirus. They
were housed in an American Association for Accreditation
of Laboratory Animal Care accredited facility in standard
indoor runs and were provided commercial dog chow and
chlorinated tap water ad libitum. Animal holding areas were
maintained at 21°C ± 1°C with 50% ± 10% relative humid-
ity using at least 15 air changes per hour of 100% condi-
tioned fresh air. The dogs were on a daily 12-hour light/dark
full-spectrum lighting cycle (LD12:12) with no twilight.
The Institutional Animal Care and Use Committee of
FHCRC approved the protocols for this study.
Thrombopoietin (rhTPO and PEG-rhMGDF)
RhTPO was provided by Zymogenetics (Seattle, WA).
Increasing doses of rhTPO were administered by subcuta-
neous injection twice a day for 7 days in 6 nonirradiated dogs
(5 µg/kg per day; 10 µg/kg per day; 15 µg/kg per day). In
5 dogs, rhTPO (10 µg/kg per day) was administered for 28 days
starting within 2 hours of a sublethal dose of TBI (200 cGy).
Five dogs received only vehicle as part of the control group.
Two dogs that developed rhTPO-specific antibodies
were re-treated with 5 or 10 µg/kg per day rhTPO begin-
ning after platelet counts had recovered after TBI.
Next, PEG-rhMGDF was provided by Amgen (Thou-
sand Oaks, CA) for studies of platelet recovery after allo-
geneic HSCT. Ten dogs were treated with PEG-rhMGDF
by subcutaneous injection (10 µg/kg per day, divided) twice
a day for 21 days, starting within 2 hours of high-dose TBI
(920 cGy). This biologically active dose of PEG-rhMGDF
was based on previous studies in dogs [23]. Ten dogs
received only the vehicle as part of the control group.
TBI, Marrow Transplantation, and Postirradiation
Care
Ten dogs were given 200 cGy TBI and 20 dogs were
given 920 cGy TBI in a single fraction at 7 cGy/min from
2 opposing 60Co sources [22]. The day of TBI was designated
as day 0. For those dogs that received HSCT after 920 cGy
TBI, a total nucleated cell (TNC) dose of 4.0 × 108 TNC/kg
of marrow from a dog leukocyte antigen [DLA]–identical lit-
termate was targeted for infusion. After TBI, parenteral ﬂu-
ids, electrolytes, platelet transfusions, and broad-spectrum
antibiotics were administered as described. After HSCT, the
intravenous formulation of cyclosporine (20 mg/kg per day)
was administered in 2 divided doses from days 0 to 6. The
oral formulation of cyclosporine (30 mg/kg per day) was
administered in 2 divided doses from days 7 to 42 [22]. All
blood products used for transfusions were irradiated in vitro
(1500 cGy) to inactivate immunologically competent cells.
Autopsies with histologic examinations of the organs were
performed on all dogs that died during the study period.
DLA Typing of Canine Littermates
Ten matched littermate donor/recipient pairs were cho-
sen for studies of allogeneic HSCT on the basis of identity
for highly polymorphic major histocompatibility complex
(MHC) class I and class II microsatellite markers [24,25].
Specific DLA DRB1 allelic identity was determined by
direct sequencing [26].
Hematology
Hematology examinations consisting of complete
blood counts and white blood cell count (WBC) differen-
tials were performed at least twice before administration of
TPO/PEG-rhMGDF and for a minimum of 5 days per
week subsequently. The samples were collected into a tube
containing EDTA. Automated hematological analyses of
blood samples were done on a Sysmex E 2500 (Baxter,
Chicago, IL). Blood smears were stained with Wright-
Giemsa for WBC differentials.
Marrow Biopsy, Aspiration, and Liver Biopsy
For bone marrow evaluations, dogs were anesthetized
by intravenous injection of fentanyl (0.4 mg/9 kg; Innovar-
Vet, Pitman-Moore, Mundelein, IL), ketamine hydrochlo-
ride (42 mg/9 kg) and acepromazine (1.7 mg/9 kg; Aveco,
Fort Dodge, IA). Marrow aspiration and biopsy specimens
were obtained before and 28 days after administration of
TPO/PEG-rhMGDF. Liver biopsies were performed under
anesthesia and ultrasound guidance if platelet count was
above 60,000/µL.
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Platelet Survival
All assessments of platelet survival were done with
autologous platelets labeled with chromium-51 [27]. Venous
blood was obtained at 1 hour after infusion of labeled
platelets and then daily for 4 days to determine the rates of
disappearance of platelet radioactivity. Platelet survival was
measured in days. An assessment of platelet survival was
done prior to administration of rhTPO to establish a base-
line value for each animal to compare with measurements
obtained weekly for 3 weeks after the start of TPO.
Serum Chemistry and Plasma Fibrinogen Levels
Serum samples from nonirradiated dogs that received
increasing doses of rhTPO were collected on day 0 before
the administration of TPO/PEG-rhMGDF and thereafter
on days 7, 14, and 21. Serum concentrations of sodium,
potassium, chloride, total CO2, creatinine, glucose, calcium,
phosphorus, urea nitrogen, uric acid, cholesterol, triglyc-
eride, albumin, globulin, total bilirubin, direct bilirubin, lac-
tic dehydrogenase (LDH), glutamic-pyruvic transaminase
(SGPT), γ-glutamyl transaminase (SGOT), γ- glutamyl
transpeptidase (GGT), and alkaline phosphatase were meas-
ured. Fibrinogen levels were measured in plasma using the
thrombin clotting time technique. The change in light scat-
ter due to ﬁbrin clot formation after the addition of Bovine
Thrombin 500 (Pacific Hemostasis, Houston, TX) was
measured in a MLA Electra 800 (Baxter).
Study of Immunized Dogs with rhTPO
Dogs that developed rhTPO-specific antibodies
after the initial treatment regimen were re-treated with
rhTPO to boost the immune response. Complete blood
counts were followed serially to assess the effect of retreat-
ment with rhTPO, and plasma was collected after the devel-
opment of thrombocytopenia. Plasmapheresis was per-
formed for 5 days, and a minimum 32 mL/kg was collected
from an rhTPO-sensitized, thrombocytopenic dog (D978)
and 2 untreated dogs. The plasma was stored in a –70°C
freezer. Red blood cells were reconstituted with saline 9%
and infused into the dog from which they had been drawn.
Plasma from the untreated (control) and from the rhTPO-
sensitized dogs was infused into untreated, normal recipient
dogs at 16 to 20 mL/kg per dose, intravenously, on days 0
and 1. Serial complete blood counts were performed. Serol-
ogy studies were performed to confirm the presence of
rhTPO-speciﬁc antibody.
Methodology for Assessing rhTPO-Specific or 
PEG-rhMGDF–Specific Antibodies
An enzyme-linked immunosorbent assay (ELISA) was
established to monitor for the presence of rhTPO-speciﬁc
antibodies in dog plasma. Ninety-six–well microtiter plates
were coated with rhTPO at 250 ng/mL diluted in coating
buffer (0.1 mol/L Na2HCO3, pH 9.6). The plates were
incubated overnight at 4°C, washed with ELISA C buffer
(phosphate-buffered saline [PBS], 0.05% Tween-20), then
blocked with ELISA B buffer (PBS, 0.1% bovine serum
albumin [BSA], 0.05% Tween-20). Test samples of dog
plasma were diluted in ELISA B buffer, added to the wells,
and incubated at 37°C for 2 hours. The test samples were
removed, the wells were washed with ELISA C, and goat
antidog immunoglobulin G conjugated to horseradish per-
oxidase (Cappell, Melvern, PA) diluted 1:2000 in ELISA B
was added to the wells for 1 hour at 37°C. The wells were
washed with ELISA C, then incubated with OPD sub-
strate solution (12.5 mL 0.1 mol/L Na citrate, pH 5.0, 5 mg
o-phenylenediamine, and 5 µL 30% H2O2). The reaction
was stopped by the addition of 1N H2SO4, and the plates
were read at absorbance 490 nm in a Dynatech ELISA plate
reader (Molecular Devices, Sunnyvale, CA).
Dogs that received PEG-rhMGDF had their samples
tested in a radioimmunoassay (RIA) and neutralizing anti-
body bioassay (modiﬁed from [23]). Data from the RIA were
expressed as the ratio of the postinjection sample over the
preinjection (baseline) sample. A reactive sample was one
with a ratio >2. All of the samples submitted had post/pre
ratios of less than 2 and were considered nonreactive. The
results of the neutralizing antibody bioassay were expressed
as titers. A titer of <1:50 was considered negative for neu-
tralizing antibodies.
Statistical Analysis
To test whether the TPO group had fewer days in which
platelet counts were below 20,000/µL, we used a randomiza-
tion test [28]. For 2 dogs in each pair, the labels of TPO and
control would be discarded when TPO had no effect on
engraftment. Therefore, 2 possible values of the difference
between 2 platelet counts could be obtained by switching the
labels within the pair. There was a total of 32 possible combi-
nations of such switches for 5 pairs. We computed the mean
of the differences for each of the 32 combinations and ranked
them. The 1-sided P value was the position of the observed
difference from the data divided by 32. To examine the time
trend for each group of dogs, a bootstrap method was used in
which all of the possible 3125 combinations of the resampling
pairs were computed [29]. The 90% conﬁdence band for each
group was computed by taking the lower 5% and upper 5%
(rounded to integer) of the ranked mean platelet measures for
each group. This result formed the 90% conﬁdence band. To
examine whether 2 groups had different time trends, we ﬁrst
computed the difference within each pair for each day and
then bootstrapped on the pair differences to form the 90%
conﬁdence band. A log(x + 1) transformation for platelets and
granulocytes was used so that the conﬁdence band for the
difference in the 2 groups at the original scale (base 10)
was the logarithm of the ratio of the 2 groups at the original
scale (TPO/control). For any day, the TPO group was judged
to have signiﬁcantly higher counts than the control group
(1-sided test, P < .05) if the lower limit of the 90% conﬁdence
band was above 1 on that day.
A Wilcoxon’s paired signed rank test was used to com-
pare the effects of PEG-rhMGDF on platelet recovery after
transplantation with the control group [30].
RESULTS
Effect of Increased Doses of rhTPO
Six normal dogs were treated with twice-daily injections
of increasing doses of rhTPO (5, 10, and 20 µg/kg per day)
subcutaneously for 7 days. All 6 dogs showed an increase in
platelet counts (Figure 1). The 5 µg/kg per day dose of
rhTPO was not as effective for increasing the platelet count
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as were the 2 higher doses. There was no apparent differ-
ence in peak platelet counts at the doses of 10 and 20 µg/kg
per day. No signiﬁcant changes in hematocrit, neutrophil, or
monocyte counts were observed after treatment compared
to baseline. An increase in serum LDH was observed (2- to
3-fold compared to baseline) with no other significant
change in serum chemistries, including albumin and choles-
terol. Platelet survival was unchanged compared to baseline
during rhTPO treatment.
Effect of rhTPO on Platelet Recovery after 200 cGy TBI
Ten dogs were given 200 cGy TBI. Dogs were irradi-
ated in matched pairs, of which one received 10 µg/kg per
day rhTPO for 28 days and the other received vehicle only
(TPO group, n = 5; control group, n = 5). The rhTPO
group had fewer days with platelet counts <20,000/µL
(9.8 days versus 17.8 days, P = .031) and fewer days with
platelet counts <10,000/µL (4.4 days versus 14.4 days,
P = .023) (Figure 2). Platelet counts in the rhTPO group
were signiﬁcantly increased compared to those of the con-
trols between days 11 and 25 after TBI. Granulocyte counts
in the rhTPO group were also significantly greater than
those of the control group between days 13 and 25 after
TBI (Figure 3). No signiﬁcant difference in median hemat-
ocrit from day 0 to day 28 was observed between the
2 groups (P = .095). One control dog died on day 27 after
TBI from infectious complications while pancytopenic.
Effect of PEG-rhMGDF on Platelet Recovery after
920 cGy TBI and Allogeneic Marrow Transplantation
Ten pairs of dogs received transplants of DLA-identical
marrow from littermates after 920 cGy of TBI. The median
cell doses infused were 3.89 × 108 TNC/kg (range, 2.09-
4.15 × 108 TNC/kg) and 4.00 × 108 TNC/kg (range, 2.06-
4.39 × 108 TNC/kg) for the PEG-rhMGDF and control
groups, respectively. PEG-rhMGDF was given in 2 divided
doses of 10 µg/kg per day, subcutaneously, for 21 days. The
median time to a sustained recovery of platelet counts
≥20,000/µL for the PEG-rhMGDF group was 14.0 days,
compared to 15.5 days for the placebo group (log rank,
P = .35). There was no difference in the number of days that
platelet counts were <20,000/µL (Figure 4). There was no
significant difference between the 2 groups in the time to
recover neutrophil counts >500/µL or in the hematocrit. No
complications associated with PEG-rhMGDF were noted.
There was no difference between the 2 groups in the occur-
rence of graft-versus-host disease (GVHD), and no GVHD
occurrence was severe.
One dog in the PEG-rhMGDF group died from infec-
tious complications while pancytopenic on day 19. Two dogs
died in the control group (at days 36 and 45), and 3 dogs
died in the PEG-rhMGDF group (at days 33, 40, and 41)
with liver necrosis after platelet recovery. The necrosis
involved the centrilobular and midzone areas of the liver.
There was significant lysis of hepatocytes with minimal
hemorrhage and residual stromal cells. No thrombosis was
observed, and there was no evidence of veno-occlusive dis-
ease of the liver. It is interesting to note that of the 4 dogs
that had routine liver biopsies performed at 6 to 10 days
before death, 3 had no evidence of liver necrosis identiﬁed.
The etiology for the liver necrosis was uncertain but may
have been related to a viral hepatitis.
TPO Sensitization
There was no evidence of sensitization to rhTPO in any
of the nonirradiated dogs that received increasing doses. All
of these dogs were followed for a minimum of 4 weeks after
completing rhTPO. Two of 5 dogs that received rhTPO
after TBI (200 cGy) were sensitized and had either a
markedly delayed recovery of platelet counts or a late
decrease in platelet counts after an initial recovery. ELISA
confirmed the presence of rhTPO-specific antibodies in
these 2 dogs. No PEG-rhMGDF–specific antibodies were
identiﬁed at day 28 after allogeneic HSCT.
The 2 rhTPO-sensitized dogs were re-treated with
rhTPO after their platelet counts had recovered to normal
Figure 1. Effect on platelet counts after treatment of 6 normal dogs
with twice-daily injections of increasing doses of rhTPO (5, 10, and
20 µg/kg per day) subcutaneously for 7 days.
Figure 2. Effect of rhTPO on platelet and granulocyte recovery after
TBI (200 cGy). Ten dogs were irradiated in matched pairs, of which
one received 10 µg/kg per day rhTPO for 28 days and the other
received vehicle only (TPO group, n = 5; control group, n = 5). Serial
platelet and granulocyte counts are presented as median values.
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levels. The ﬁrst retreatment of the 2 rhTPO-sensitized dogs
(D978, E080) with rhTPO 10 µg/kg per day, 7 days apart for
a total of 2 days, resulted in the recurrence of thrombocy-
topenia with platelet counts as low as 16,000/µL and
61,000/µL, respectively (Figure 5). Platelet counts persisted
<100,000/µL for 13 and 3 weeks after the retreatment,
respectively. During the period of thrombocytopenia induced
by the administration of rhTPO, platelet survival in the
peripheral circulation was normal. Results of serial multiple
marrow biopsies showed that the megakaryocyte content was
normal or reduced to between 10% to 30% of normal in dogs
E080 and D978. Plasma from dog D978 and from untreated
dogs was infused into normal dogs to evaluate the effect on
platelet counts. There was a gradual modest reduction in
platelet counts in the 3 dogs infused with plasma from D978.
The 3 dogs had baseline platelet counts of 323,000/µL,
167,000/µL, and 337,000/µL and nadirs of 125,000/µL at day
17, 50,000/µL at day 29, and 84,000/µL at day 25, respec-
tively. No signiﬁcant changes in platelet counts were associ-
ated with the infusion of normal plasma. There was no
change in platelet survival after plasma infusion.
DISCUSSION
The recombinant ligands for c-mpl (rhTPO and PEG-
rhMGDF) have been used in preclinical models of myelo-
suppression and in clinical studies of myelosuppression to
evaluate their effect on hematopoietic reconstitution.
Although the study was initiated with rhTPO in normal
dogs and in the low-dose TBI model, studies of platelet
recovery after allogeneic HSCT were done with PEG-
rhMGDF. There have been no direct comparisons between
rhTPO and PEG-rhMGDF, but both molecules have the
same c-mpl binding site, which is critical for the biological
activity of the ligand. PEG-rhMGDF had previously been
studied in dogs and was known to be biologically active [23].
The dose of PEG-rhMGDF (10 µg/kg per day for 21 days)
in the study was at least comparable and probably several-
fold more biologically active than the dose of rhTPO shown
to be active after low-dose TBI in the earlier phase of this
study [7,31]. Comparable doses and schedules of these
2 agents have been used in these previously reported pre-
clinical studies. Administration of recombinant ligands for
c-mpl to normal animals following myelosuppressive ther-
apy with TBI or chemotherapy has been shown to decrease
the severity and shorten the duration of thrombocytopenia
as well as, in some cases, neutropenia [7,8,10,14,19-21,31-34].
The improved recovery of both platelet and granulocyte
counts with rhTPO treatment after TBI (200 cGy) in dogs
is consistent with these previous studies of rhTPO after
myelosuppressive therapy in other species. Clinical studies
of recombinant c-mpl ligand after myelosuppressive therapy
have had mixed results. After dose-intensive chemotherapy
Figure 3. Ninety percent conﬁdence band for the difference between
treatment and control groups. For examination of the time trend of
platelet and granulocyte recovery after TBI (200 cGy) for each group
of dogs, a bootstrap method was used. The 90% confidence band
(upper and lower lines) for each group was computed by taking lower
5% and upper 5% of the ranked mean platelet measures for each
group. For any day, the TPO group was judged to have signiﬁcantly
higher counts than the control group (1-sided test, P < .05) if the low
limit of the 90% conﬁdence band was above 1 on that day. Platelet (A)
and granulocyte (B) counts in the rhTPO group were significantly
increased compared to those of the controls, predominantly between
days 11 and 25 and between days 13 and 23 after TBI, respectively.
Figure 4. Effect of PEG-rhMGDF on platelet and granulocyte recov-
ery after TBI (920 cGy) and allogeneic HSCT from DLA-identical lit-
termates. No difference in time to recovery of platelets or granulocytes
was observed between the 2 groups.
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for solid tumors, the platelet nadir was increased and the
duration of thrombocytopenia was reduced with c-mpl
ligand therapy [35,36]. However, after induction chemo-
therapy for acute myelogenous leukemia, time to achieve a
platelet count of at least 20,000/µL was not affected by c-mpl
ligand therapy, although later platelet counts were increased
in the treatment group [37,38]. The effectiveness of c-mpl
ligand therapy after myelosuppression may depend on clini-
cal factors, including type of disease, type and intensity of
cytotoxic therapy, and the dose and schedule of recombinant
c-mpl ligand.
Early studies in a murine HSCT model after otherwise
lethal TBI showed that recombinant c-mpl ligand enhanced
platelet recovery [39-41]. However, the administration of
c-mpl ligand did not shorten the duration of severe throm-
bocytopenia or granulocytopenia in preclinical (large animals)
or clinical studies of myeloablative therapy and autologous
HSCT [42-46]. After allogeneic HSCT, additional risk fac-
tors for delayed platelet recovery include the presence of
GVHD, HLA disparity, and therapeutic immunosuppres-
sion (eg, cyclosporine) [2,3]. Moreover, after allogeneic
HSCT there is an increased risk of late failure of platelet
recovery [1]. In spite of or because of these additional risk
factors, no effect of c-mpl ligand therapy was observed on
the time to platelet recovery after allogeneic HSCT in dogs.
Although it would not be expected because c-mpl is not
expressed on immunologically active cells, c-mpl ligand
therapy was not associated with an increased risk of GVHD.
No other preclinical studies of c-mpl ligand therapy after
allogeneic HSCT have been reported in large animals or
humans. A dose-finding clinical study in patients with
significantly delayed platelet recovery has investigated
rhTPO therapy after either autologous or allogeneic HSCT
[47]. The start of rhTPO therapy was a median of 65 days
(range, 40-129 days) after transplantation. Although this was
a dose-ﬁnding study, a therapeutic effect of c-mpl ligand on
platelet recovery was not readily apparent. No effect on the
development of GVHD was noted.
In the PEG-rhMGDF study, episodes of liver necrosis
occurred in the dogs after allogeneic stem cell transplanta-
tion. These episodes did not interfere with the evaluation of
the effect of PEG-rhMGDF on platelet recovery because
liver necrosis was diagnosed after platelet recovery in most
cases. Events of liver necrosis occurred in both arms of the
study, and therefore we concluded that it was not a toxicity
of PEG-rhMGDF. The cause of the liver necrosis is uncer-
tain. Cyclosporine is known to have toxic effects on the
liver. However, this dose has been tolerated well in many
previous studies of GVHD in this model. A viral cause was
also considered because after this study was completed, con-
ﬁrmed episodes of viral hepatitis (herpes) were noted in the
dog colony. The liver pathology was comparable to that
observed with viral hepatitis.
The development of neutralizing antibodies against
human TPO or human PEG-rhMGDF has been docu-
mented in 2 different preclinical studies. In the ﬁrst study,
chronic administration of PEG-rhMGDF to dogs resulted
in a prolonged period of severe thrombocytopenia. Recov-
ery of platelet counts to >100,000/µL from the nadir
occurred over 3 months [23]. In a second study in mice, a
TPO knock-out phenotype developed after neutralizing
antibodies against human TPO were induced by the infu-
sion of a recombinant adenovirus encoding human TPO
[48]. A chronic immune thrombocytopenia persisted as long
as 8 to 10 months after treatment. Treatment with TBI (500
cGy) before the infusion of the recombinant adenovirus
encoding human TPO prevented the development of
thrombocytopenia in some mice. In dogs, TBI (200 cGy)
before rhTPO treatment was not sufﬁcient to prevent sensi-
tization and the development of thrombocytopenia. The
development of sensitization to rhTPO in the dogs was
likely promoted by the cross-species difference. It is possible
that the risk of sensitization to rhTPO may be less with
intravenous infusion than with subcutaneous injection.
Plasma from the rhTPO-sensitized dog was infused into
normal dogs; it resulted in a decreased platelet count, con-
sistent with the conclusion that rhTPO-speciﬁc antibodies
alone induce thrombocytopenia. Platelet survival studies
were normal, indicating that the rhTPO-speciﬁc antibodies
decreased the production of platelets or the release of
platelets into the peripheral circulation.
The development of neutralizing antibodies with the
resultant thrombocytopenia in preclinical models was pre-
dictive of complications in clinical trials. This observation is
important because the likely mechanism for the develop-
ment of thrombocytopenia is the production of antibodies
to rhTPO that cross-reacted and neutralized the native
canine form of TPO. Patients have developed neutralizing
antibodies speciﬁc for PEG-rhMGDF in a study of chemo-
therapy-induced thrombocytopenia and in another study
with normal individuals. Thrombocytopenia was noted to
develop in some patients with the occurrence of the neutral-
izing antibodies [49-51]. The development of neutralizing
antibodies and clinically significant thrombocytopenia in
Figure 5. Retreatment of rhTPO-sensitized dogs to boost immune
response. Two of 5 dogs were sensitized to rhTPO after TBI (200 cGy).
The ﬁrst retreatment with rhTPO of 10 µg/kg per day, 7 days apart for
a total of 2 days, resulted in the recurrence of thrombocytopenia to a
platelet count as low as 16,000/µL and 61,000/µL. The second retreat-
ment with rhTPO of 5 µg/kg per day, 7 days apart for a total of 2 days
of the 2 dogs (D978, E080) also resulted in the development of throm-
bocytopenia of a similar severity and duration. ↓ indicates treatment of
sensitized dogs with rhTPO.
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some individuals after receiving PEG-rhMGDF resulted in
the discontinuation of clinical trials of this agent in the
United States [49]. To date, no rhTPO-speciﬁc neutralizing
antibodies have been detected in any of the clinical trials
(Beryl Hartley-Asp, Pharmacia, personal communication,
February 2002).
In dogs, c-mpl ligand had a modest effect on recovery of
platelet counts after low-dose myelosuppression but had no
effect on platelet recovery after allogeneic HSCT. Sensitiza-
tion to rhTPO after low-dose TBI resulted in transient but
signiﬁcant episodes of thrombocytopenia in some dogs. No
neutralizing antibodies were detected after allogeneic mar-
row transplantation. The potential development of neutral-
izing antibodies and subsequent thrombocytopenia after
low-dose myelosuppression may limit the clinical role of
recombinant c-mpl ligands until further information is
available on its prevention or until there is a high degree of
certainty that it will not occur in humans with the type of
c-mpl ligand being administered.
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